, Volume 92, Issue 4, pp 567-568

Remission of primary cutaneous anaplastic large cell lymphoma after a brief course of brentuximab vedotin

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access
This is an excerpt from the content

Dear Editor,

We evaluated a 74-year-old Caucasian man with multiple previous recurrences of primary cutaneous anaplastic large cell lymphoma (PCALCL) between 2003 and 2010 involving his scalp, forearms, shoulders, and trunk as solitary papules or nodules. They had been treated with excisions, topical carmustine, or focal electron beam radiotherapy (EBRT). In 2011, the patient received 4,000-cGy EBRT to a new lesion on the left calf and 3,600-cGy tomotherapy to adjacent tumors in January 2012. Treatment was complicated with extensive lymphedema, cellulitis, and ulcerative dermatitis requiring debridement, intravenous antibiotics and resulting in nonhealing wounds. In June 2012, numerous rapidly growing nodules appeared on the patient’s left thigh, without evidence of systemic involvement (Fig. 1a). Biopsy consistently demonstrated CD30-positive, anaplastic lymphoma kinase (ALK-1)-negative PCALCL (Fig. 1b). This multifocal recurrence necessitated systemic therapy, but the disease progress